UpdatesPress Release
Akums posted robust Q4 & FY26 results: Revenue up 9.7% to ₹1,158 Cr (Q4) & 5.9% to ₹4,359 Cr (FY26), with Adj PAT surging 135% (Q4) & 27.3% (FY26). CDMO business drove growth.
Akums Drugs and Pharmaceuticals LimitedAKUMS · Filed with the exchange
Global expansion continued; API segment faces pricing pressure.
Board declared a ₹3/share dividend.
No comments yet. Be the first.